In the past, glucocorticoids in allergic features and ursodeoxycholic acid in cholestatic cases had been used, but there is no good evidence to support their effectiveness
In a randomized, placebo-controlled study, pemvidutide, a dual GLP-1/GCG receptor agonist, significantly decreased liver fat content by up to 68.5% after 12 weeks of treatment, accompanied by reductions in hepatic inflammation markers and body weight, highlighting the potential of dual receptor agonists to modify MASLD pathophysiology (47)
L-carnitine optimises fat oxidation and increases endurance performance
The GLP-1RA drugs semaglutide and liraglutide, due to their longer half-lives, may have more prolonged effects in the CNS and regulate appetite metabolic processes (30)
Whether it gets approved for both indications depends on Phase 3 trial outcomes